Call for Abstract
Scientific Program
8th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems, will be organized around the theme “Challenges and Advances in Novel Drug Delivery Systems”
Pharmaceutica 2016 is comprised of 15 tracks and 79 sessions designed to offer comprehensive sessions that address current issues in Pharmaceutica 2016.
Submit your abstract to any of the mentioned tracks. All related abstracts are accepted.
Register now for the conference by choosing an appropriate package suitable to you.
Pharmaceutics is the study of relationships between preformulation, drug formulation, delivery, disposition and clinical response. The inherent instability nature of a new drug will alter its desired form into undesired form when presented in a suitable dosage form with the excipient/s upon storage. In early days this process was confined only for assessing few characteristics, but today this process is being considered as a formulation strategy and the tremendous technological advancement has been achieved in this field which enables us to save time and money through planned management system and hence impacts Pharmaceutica 2016 to be a formulation conference. Use of glorious statistical software even based on artificial neural networking are made the task of preformulation and optimization process easier. Role of preformulation studies techniques like freeze drying aspects projects the event Pharmaceutica 2016 to pose as a freeze drying meeting in drug discovery, drug development plays major role in pharmaceutical formulation development and the studies will help in different dosage forms design. With the increasing number of novel and specialized compounds being developed, a "one size fits all" approach to drug formulation and delivery is no longer optimal, necessitating the consideration of formulations unique to each drug. NDDS conference will discuss on Early Approaches, Present Scenario and Future Prospects of Preformulation events. Pharmaceutical conferences discusses the state-of-the-art technology being applied and advances in formulation studies.
Revenues within the global generics market reached an estimated value of $265 b in 2012, showing a growth of 9.3% throughout the year. The contribution of generics is approximately 20% of overall international pharmaceutical market. The utilization of generic in terms of volume is higher in the US and lower in Japan, 89% and 24% respectively.
- Track 1-1Role of preformulation studies in drug discovery
- Track 1-2Role of preformulation studies in drug development
- Track 1-3Preformulation studies for generic products
- Track 1-4Stability studies and regulatory considerations
- Track 1-5Preformulation considerations for different dosage forms
- Track 1-6Applications of analytical techniques in preformulation studies
There are various anatomical routes which thought them medical drugs can be administered into the human body. The selection of the route depends on three factors which are:
- The effect desired
- The type of the disease and finally
- The type of the product.
The most common routes of drug administration include the following:
Oral route, this is the oldest route which has been used for conventional and novel drug delivery administration. Parenteral route, these routes include intramuscular, intravenous, intra-arterial and subcutaneous route. Transdermal route, this route the medical treatment will apply on the body surfaces such as the skin and / or mucous membrane. Inhalation route, In this type of medical treatment application route, the medical treatment will directly reach the lungs, by this way this route considers the route of choice to avoid systemic effect i.e., increase the bioavailability of the drug in the system.
- Track 2-1Advances in oral and nasal drug delivery
- Track 2-2Developments in ophthalmic drug delivery systems
- Track 2-3Topical drug delivery system
- Track 2-4Transdermal drug delivery system
- Track 2-5Parenterals and implants in drug delivery
- Track 2-6Rectal and vaginal drug delivery
- Track 2-7Novel routes for insulin delivery
Drug delivered can have significant effect on its efficacy. Some drugs have an optimum concentration range with in which maximum benefit is derived and concentrations above (or) below the range can be toxic or produce no therapeutic effect. Various drug delivery and drug targeting systems are currently under development and being showcased in various targeted drug delivery systems conferences and Novel Drug Delivery system conferences across the globe. The main goal for developing such delivery systems is to minimize drug degradation and loss, to prevent harmful side effects and to increase bioavailability. Targeting is the ability to direct the drug loaded system to the site of interest. New drug carriers systems are one can name soluble polymers, micro particles made of insoluble (or) biodegradable natural and synthetic polymers, microcapsules, cells, cell ghosts, lipoproteins, liposomes and micelles. Pharmaceutica 2016 evolves to be a drug disintegration conference, emulsion conference, capsule conference, and solubility conference.
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, and Peptisyntha Inc. at the pharmaceutical companies’ conference.
The oral drug delivery market remains the largest slice of the overall drug delivery market, with more than 52% of the market share. It is presently valued at $49 billion and is expected to reach over $90 billion by 2016, at a CAGR of 11%. The growth in the oral drug delivery market shall be driven primarily by newer technologies enabling controlled release formulations of oral drugs and oral formulations of injectable only drugs.
- Track 3-1New drug carriers systems
- Track 3-2General mechanisms consideration
- Track 3-3Prodrugs
- Track 3-4Pharmaceutical applications
- Track 3-5Administration routes
- Track 3-6Nanoparticles technology
Drug Targeting to specific organs and tissues has become one of the critical endeavours of the century since the use of free drugs in conventional dosage forms generally involves difficulties in achieving the target site at the appropriate dose after or during a proper time period. Consequently, the search for new drug delivery approaches and new modes of action represent one of the frontier research areas. Major discussion on this session includes Applications of drug targeting, Targeting approaches, Issues in drug targeting, Brain targeted drug delivery system and Antibody targeted-drug conjugates. Pharmaceutica 2016 is considered to be a BBB drug delivery meeting and the conference offers more discussions on Challenges and advancements in blood brain barrier targeted drug delivery.
The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
- Track 4-1Applications of drug targeting
- Track 4-2Targeting approaches
- Track 4-3Issues in drug targeting
- Track 4-4Brain targeted drug delivery system
- Track 4-5Antibody targeted-drug conjugates
Nanotechnology has finally and firmly entered the realm of drug delivery. Performances of intelligent drug delivery systems are continuously improved with the purpose to maximize therapeutic activity and to minimize undesirable side-effects. There are multiple Applications of Nanotechnology in Drug Delivery systems are based on micelles, polymeric nanoparticles, and dendrimers. Polymeric carbon nanotubes and many others demonstrate a broad variety of useful properties. The following dosage forms using Nanotechnology in Drug Delivery Systems are Liposomes as potential drug carrier systems for drug delivery and project Pharmaceutica 2016 to pose as a liposome event during the conference , Techniques for the preparation of solid lipid nano and microparticles, Nanoemulsions applications, Nanoparticle based Drug Delivery Systems for Treatment of Infectious Diseases, Dermal, Transdermal Drug Delivery, Insulin Drug Delivery and Organic Nanotubes as a Promising Vehicles for Drug Delivery. NDDS conference will discuss on the Current Status and Future Scope for Nanomaterials in Drug Delivery and reflect on pharmaceutical technology conference. Interestingly pharmaceutical sciences are also using nanoparticles to reduce toxicity and side effects of drugs. The potential to cross the Blood Brain Barrier (BBB) has open new ways for drug delivery into the brain. In addition, the nanosize also allows for access into the cell and various cellular compartments including the nucleus. Nanoparticles are also considered to have the potential as novel intravascular or cellular probes for both diagnostic and therapeutic purposes (drug/gene delivery), which is expected to generate innovations and play a critical role in medicine.
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, Peptisyntha Inc. and Lonza Inc.
The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
- Track 5-1Nanocarriers & their applications
- Track 5-2Targeting strategies
- Track 5-3Key factors impacting drug delivery
- Track 5-4Challenges of nanotechnology for drug delivery
- Track 5-5Future perspective
- Track 5-6Impact of nanoscience and nanotechnology on controlled drug delivery
Nanotechnology has finally and firmly entered the realm of drug delivery. Performances of intelligent drug delivery systems are continuously improved with the purpose to maximize therapeutic activity and to minimize undesirable side-effects. The primary goals for research of nano-bio-technologies in drug delivery include
- More specific drug targeting and delivery,
- Reduction in toxicity while maintaining therapeutic effects,
- Greater safety and biocompatibility, and
- Faster development of new safe medicines
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group, Peptisyntha Inc. and Lonza Inc.
The global market for blood-brain barrier (BBB) technology for therapeutics reached $21.8 million in 2013. This market is expected to grow from $38.7 million in 2014 to $471.5 million in 2019, a compound annual growth rate (CAGR) of 64.9% from 2014 through 2019.
- Track 6-1Liposomes as potential drug carrier systems for drug delivery
- Track 6-2Techniques for the preparation of solid lipid nano and microparticles
- Track 6-3Nanoemulsions and its applications in drug delivery
- Track 6-4Nanoparticle based drug delivery systems for treatment of infectious diseases
- Track 6-5Nanoparticles for dermal and transdermal drug delivery
- Track 6-6Nanoparticle Insulin drug delivery — Applications and new aspects
- Track 6-7Organic nanotubes: Promising vehicles for drug delivery
- Track 6-8Current status and future scope for nanomaterials in drug delivery
Major Challenges in Drug Delivery Systems are delivery of poorly soluble drugs and bioavailability hurdles for poorly soluble clinical candidates. There are several Novel approaches in the delivery, Overcoming bioavailability hurdles and Rationale formulation design of poorly soluble drugs. Other Major Challenges in Drug Delivery are protein drug delivery, paediatric and geriatric drug delivery. Self-emulsifying drug delivery systems (SEDDS) possess unparalleled potential in improving oral bioavailability of poorly water-soluble drugs. Taking dosage form into consideration makes the event Pharmaceutica 2016 a dosage form meeting.
There is an increasing demand for effective and, ideally, non-invasive drug-delivery methods. This is especially the case for the biopharmaceutical sector, which has experienced an overwhelming growth due to advances in biotechnology. In 2009, over $12 billion were invested in biologics / biotechnology research and development (R&D), representing a 26% share in the total R&D expenditure. A recent report by the Pharmaceutical Research and Manufacturers of America (PhRMA) states that in 2015 there were 901 biological in development, targeting more than 100 diseases.
- Track 7-1Problems involved and overcoming challenges in the delivery of poorly soluble drugs
- Track 7-2Novel approaches in the delivery of poorly soluble drugs
- Track 7-3Overcoming bioavailability hurdles for poorly soluble clinical candidates
- Track 7-4Rationale formulation design for poorly soluble compounds
- Track 7-5Overcoming challenges in protein drug delivery
- Track 7-6Challenges in pediatric and geriatric drug delivery
- Track 7-7Overcoming addictive nature of drugs
- Track 7-8Advances in self-emulsifying drug delivery systems (SEDDS)
Drug Delivery system method by which a drug is delivered can have a significant effect on its efficacy. NDDS Conference includes topics like Anatomical, biochemical and physiological considerations in design and development of novel drug delivery systems, Pharmacokinetics in drug design, Pharmacokinetic behaviour of conventional and novel dosage forms, In-silico drug discovery and development, Computational methods in ADME and toxicity studies, Pharmacokinetic parameters for drug input and drug disposition.
The global revenue for advanced drug delivery systems is estimated to be $151.3 billion in 2013. In 2018, revenues are estimated to reach nearly $173.8 billion, demonstrating a compound annual growth rate (CAGR) of 2.8%.
- Track 8-1Anatomical, biochemical and physiological considerations in design and development of novel drug delivery systems
- Track 8-2Pharmacokinetics in drug design
- Track 8-3Pharmacokinetic behaviour of conventional and novel dosage forms
- Track 8-4In-silico drug discovery and development
- Track 8-5Computational methods in ADME and toxicity studies
- Track 8-6Pharmacokinetic parameters for drug input and drug disposition
In Vaccine Drug Delivery there are multidisciplinary scientific field that is currently undergoing rapid development. An important component of cancer vaccines is the development of novel vaccine delivery strategies; this session includes Importance of immunostimulatory adjuvant, Advances in Vaccine Drug Delivery, Laser technology for Vaccine Delivery, Challenges and opportunities For Vaccine Delivery, Jet injectors and micro needles, Development of colloidal vaccine drug delivery systems.
Global revenue for vaccine technologies was nearly $31.8 billion in 2011. This market is expected to increase from $33.6 billion in 2012 to $43.4 billion in 2017 at a compound annual growth rate (CAGR) of 5.3%.
- Track 9-1Development of colloidal vaccine drug delivery systems
- Track 9-2Needle free vaccine drug delivery approach
- Track 9-3Laser technology for vaccine delivery
- Track 9-4Novel trends in vaccine drug delivery
- Track 9-5Jet injectors and microneedles
- Track 9-6Vaccines for cancer chemotherapy
Biotherapeutics conference session is beginning to change for small, medium, and large scale pharmaceutical & biotechnology companies which can manifest from development to manufacturing. Addressing these instabilities is a great challenge, because of the complexity of the bio therapeutics themselves. This session includes Design and development of biotherapeutics, Tools for biotherapeutics generation, Dry biopharmaceuticals and applications, Biopharmaceutical drugs from natural sources, Formulation techniques for biopharmaceuticals, RNAi, Gene therapeutics, Nucleic acid and Cell therapy. Pharmaceutica 2016 majorly projects to be a biotherapeutics conference with vast scope of future advances and inventions.
Key players profiled in this report include Boehringer Ingelheim GmbH, Catalent Pharma Solutions, Inc., DSM, Fareva, Lonza Group, Patheon, Inc., Piramal Healthcare, Accellent, Symmetry Medical, Inc. and Greatbatch, Inc.
The global market for pharmaceutical and biopharmaceutical contract manufacturing, research and packaging was $219.9 billion in 2012. This market is estimated to reach $242.2 billion in 2013 and $374.8 billion by 2018, a five-year compound annual growth rate (CAGR) of 9.1%.
- Track 10-1Biopharmaceutical drugs from natural sources
- Track 10-2Formulation techniques for biopharmaceuticals
- Track 10-3RNAi, Gene therapeutics, Nucleic acid and Cell therapy
- Track 10-4Design and development of biotherapeutics
- Track 10-5Tools for biotherapeutics generation
- Track 10-6Dry biopharmaceuticals and applications
In this session we will focus on medical devices designed for drug delivery through the pulmonary and nasal routes. These routes are of interest for local delivery, as in asthma, but also for rapid delivery of drugs to the system circulation and direct delivery to the central nervous system. Devices that account for specific anatomical and physiological features of the intranasal and pulmonary routes will be featured. Drug delivery devices are specialized tools for the delivery of a drug or therapeutic agent via a specific route of administration. Such devices are used as part of one or more medical treatments. Many in the industry have long felt overly burdened by what they consider to be an unnecessarily complex approval process. Critics claim it impedes innovation and delays the availability of better health care. In order to help innovators bring health care to the public Pharmaceutica 2016 hosts drug delivery conferences throughout the year which happened to be the event pharma conference dubai in 2015.
To change that perception, the FDA last year announced $40 million to a new Medical Device Innovation Consortium (MDIC) charged with simplifying the process of designing and testing new technologies. With input from industry, government, and other non-profit organizations, public-private MDIC will prioritize the regulatory science needs of the medical device community and fund projects to streamline the process.
The drug-device combination market is not fragmented and the key players in this market are Medtronic, Boston Scientific Corp., Edwards Life sciences Corp., Stryker Corp., QLT Inc. etc. The maximum number of new product developments is expected to take place in the bone graft substitutes, advanced wound care products and antimicrobial catheter markets. Our patent analysis indicates that E.U. has filed for the maximum number of patents followed by the U.S.
- Track 11-1CNS biodistribution from differential nasal delivery
- Track 11-2Regulatory requirements
- Track 11-3Increasing patient compliance using microelectronic technology
- Track 11-4Considerations and challenges of self injection device development
- Track 11-5Needle-free, needle array and safety syringe drug delivery system
- Track 11-6Smart, MEMS based drug delivery systems
- Track 11-7Quality by Design (QbD)
- Track 11-8Biocompatibility/Compliance testing
- Track 11-9Regulatory audits CAPA and risk management
To maximize knowledge of the current researcher on developing drug delivery via smart polymers, Smart Drug Delivery i.e. NDDS conference themed quality topics on Polymer Nanoparticles for smart drug delivery, pH and Environmental sensitive, BioMEMS smart drug delivery system, Delivery through Versatile polymers in drug delivery are a uniquely architect session to play an important role in the fields of nanotechnology, pharmaceutical and medicinal chemistry and hence a pharmaceutics conference.
Major drugs driving growth of the overall smart drug delivery market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex.
- Track 12-1Biomaterials - Scope and applications
- Track 12-2Polymer nanoparticles for smart drug delivery
- Track 12-3pH and environmental sensitive
- Track 12-4BioMEMS smart drug delivery system
- Track 12-5Delivery through versatile polymers
Major drugs driving growth of the overall peptide therapeutics market include Angiomax, Copaxone, Forteo, Sandostatin, Velcade, Victoza and Zoladex. As these drugs lose their patent exclusivity in the near future, the market for generic peptide drugs would flourish. However, difficulty in synthesis of complex peptides has restricted growth of the generic peptide drugs market.
Key players in the market include Amgen, Inc., AstraZeneca plc, Eli Lilly & Co., Ipsen S.A., Merck & Co., Novartis AG, Novo Nordisk A/S, Roche Holdings AG, Sanofi, Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Limited. Leading API manufacturers include Bachem Holding AG, PolyPeptide Group.
- Track 13-1Peptide vector for biologics brain delivery
The global market for Business Development of Drug Delivery Technology in 2010 was $131.6 billion and is expected to rise at a compound annual growth rate (CAGR) of 5% and reach nearly $175.6 billion by 2016. The U.S. constituted approximately 59% of the total drug delivery market in 2010 and was $78 billion. It is forecast to reach nearly $103 billion in 2016 at a CAGR of 4.7%. Europe contributed about 27% of the total drug delivery market in 2010 and was $36 billion and is expected to grow to $49 billion by 2016 at a CAGR of 5.6% for 2013, Drug Delivery Global market reached $150.3 billion, according to BCC research. This was an increase from $142 billion the previous year. Given its predicted annual growth the market represents a considerable business opportunity, which has been reflected in the increasing number of drug delivery specialists.
Consistent quality and competitive costs of product improves Production performance and continuity of supply and Product and technology auditing and due diligence with minimizing Regulatory Issues, quality control, and business development Business opportunities in drug delivery.
A platform aimed to connect Entrepreneurs, Proposers and the Investors worldwide. It's intended to create and facilitate the most optimized and viable meeting place for engaging people in global business discussions, evaluation and execution of promising business ideas. An investor could be able to find out the highest potential investment opportunities globally, which provide good return on investment. For entrepreneurs, this would be an ideal place to find out suitable investors and partners to start and/or expand their business. Thus it is a perfect place to connect Entrepreneurs, Business Owners, Early Stage Companies and Established Corporates with National or International Investors, Corporate Investors and Potential Business Partners.